MHC class I polypeptide-related sequence A (MICA) is a stress-induced protein involved in activation of NK and T cells through interaction with NKG2D receptor. These molecules are atypically expressed in synovium of patients diagnosed with rheumatoid arthritis (RA). A total of 279 patients with RA, qualified to TNF-blockade therapy, were genotyped for MICA rs1051792 SNP. The effectiveness of anti-TNF agents was assessed with European League Against Rheumatism criteria. Significant relationship between MICA rs1051792 and outcome of TNF-blockade therapy has been found. The MICA rs1051792 GG genotype was overrepresented in patients non-responsive to anti-TNF drugs in comparison with other genotypes (p = 0.010). On the other hand, beneficial therapeutic response was more frequently detected among RA subjects possessing heterozygous genotype than those with homozygous genotypes (p = 0.003). Furthermore, increased MICA concentrations in serum were observed in patients possessing MICA rs1051792 GG genotype as compared with those with GA or AA genotypes (p = 1.8 × 10-5). The results from this study indicate the potential influence of MICA rs1051792 polymorphism on modulation of therapeutic response to TNF-blockade treatment in RA.

中文翻译：

---

类风湿性关节炎患者 MICA-129Met/Val 多态性与抗 TNF 治疗的临床结果和 MICA 血清水平的关联。

MHC I 类多肽相关序列 A (MICA) 是一种应激诱导蛋白，通过与 NKG2D 受体的相互作用参与 NK 和 T 细胞的激活。这些分子在诊断为类风湿性关节炎 (RA) 的患者的滑膜中异常表达。共有 279 名符合 TNF 阻断治疗条件的 RA 患者进行了 MICA rs1051792 SNP 基因分型。根据欧洲抗风湿病联盟标准评估抗 TNF 药物的有效性。已发现 MICA rs1051792 与 TNF 阻断治疗的结果之间存在显着关系。与其他基因型相比，MICA rs1051792 GG 基因型在对抗 TNF 药物无反应的患者中过多（p = 0.010）。另一方面，在具有杂合基因型的 RA 受试者中比具有纯合基因型的受试者更频繁地检测到有益的治疗反应（p = 0.003）。此外，与具有 GA 或 AA 基因型的患者相比，在具有 MICA rs1051792 GG 基因型的患者中观察到血清中 MICA 浓度增加（p = 1.8 × 10-5）。这项研究的结果表明 MICA rs1051792 多态性对调节 RA 中对 TNF 阻断治疗的治疗反应的潜在影响。